Coustan-Smith Elaine, Sancho Jose, Behm Frederick G, Hancock Michael L, Razzouk Bassem I, Ribeiro Raul C, Rivera Gaston K, Rubnitz Jeffrey E, Sandlund John T, Pui Ching-Hon, Campana Dario
Department of Hematology-Oncology, St Jude Children's Research Hospital and the University of Tennessee, Memphis, TN 38105, USA.
Blood. 2002 Jul 1;100(1):52-8. doi: 10.1182/blood-2002-01-0006.
Early clearance of leukemic cells is a favorable prognostic indicator in childhood acute lymphoblastic leukemia (ALL). However, identification of residual leukemic cells by their morphologic features is subjective and lacks sensitivity. To improve estimates of leukemia clearance, we applied flow cytometric techniques capable of detecting 1 leukemic cell in 10,000 or more normal cells and prospectively measured residual leukemia in bone marrow samples collected on day 19 of remission-induction chemotherapy from 248 children with newly diagnosed ALL. In 134 samples (54.0%), we identified at least 0.01% leukemic cells (0.01%-< 0.1% in 51 samples [20.6%], 0.1%-< 1% in 36 [14.5%], and > or = 1% in 47 [19.0%]). Among 110 children treated within a single chemotherapy program, the 5-year mean +/- SE cumulative incidence of relapse or failure to achieve remission was 32.2% +/- 6.5% for the 59 patients with 0.01% residual leukemic cells or greater on day 19 and 6.0% +/- 3.4% for the 51 patients with less than 0.01% leukemic cells (P <.001). The prognostic value of day-19 bone marrow status defined by flow cytometry was superior to that defined by morphologic studies and remained significant after adjustment for other clinical and biologic variables. Lack of detectable leukemic cells on day 19 was more closely associated with relapse-free survival than was lack of detectable residual disease at the end of remission induction (day 46). Thus, approximately half of the children with ALL achieve profound clearance of leukemic cells after 2 to 3 weeks of remission-induction chemotherapy, and these patients have an excellent treatment outcome.
白血病细胞的早期清除是儿童急性淋巴细胞白血病(ALL)的一个良好预后指标。然而,通过白血病细胞的形态学特征来识别残留白血病细胞具有主观性且缺乏敏感性。为了更好地评估白血病清除情况,我们应用了流式细胞术,该技术能够在一万个或更多正常细胞中检测到1个白血病细胞,并对248例新诊断ALL儿童在诱导缓解化疗第19天采集的骨髓样本中的残留白血病进行前瞻性测量。在134份样本(54.0%)中,我们检测到至少0.01%的白血病细胞(51份样本[20.6%]为0.01% - <0.1%,36份[14.5%]为0.1% - <1%,47份[19.0%]为≥1%)。在单一化疗方案治疗的110例儿童中,第19天残留白血病细胞≥0.01%的59例患者5年复发或未缓解的平均±标准误累积发生率为32.2%±6.5%,而残留白血病细胞<0.01%的51例患者为6.0%±3.4%(P<0.001)。流式细胞术定义的第19天骨髓状态的预后价值优于形态学研究定义的预后价值,在对其他临床和生物学变量进行校正后仍具有显著性。第19天未检测到白血病细胞与无复发生存的相关性比缓解诱导结束时(第46天)未检测到残留疾病更为密切。因此,约一半的ALL儿童在诱导缓解化疗2至3周后实现了白血病细胞的深度清除,这些患者的治疗结局良好。